not only me!
CRITERION: Tim Boreham | November 03, 2009
Article from: The Australian
...
Still on the topic of punting, the biotech sector is proving to be the real stayer on the bourse, having gained 114 per cent since the start of calendar 2009.
According to Biotech Daily's index of the top 40 stocks, the sector surged 7.3 per cent in October, when the overall market took a 2 per cent breather. Notably, the index excludes the established CSL, Cochlear and Resmed, down 7 per cent for the year.
October's best performers, the Daily said, were Avexa (AVX, 18.5c, up 53 per cent), Cathrx (CXD, 65c, up 50 per cent) and Antisense Therapeutics (ANP, 7.1c, up 31 per cent).
Then followed: Living Cell (LCT, 27c), Universal Biosensors (UBI, $1.72), Bone Medical (BNE, 20c), Bionomics (BNO, 32.5c), Sirtex (SRX, $5.89) and Heartware International (HIN, 99c).
Criterion has a speculative buy on Avexa, Cathrx, Living Cell and Universal Biosensors and (as yet) no opinion on the others.
- Forums
- ASX - By Stock
- AVX
- nice timing for an avx double deal
nice timing for an avx double deal, page-7
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)